Producer
Bracco Imaging
Italian contrast-media maker (Isovue/iopamidol).
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Bracco Imaging supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Bracco Imaging makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Contrast Media (CT / MRI)
Ultrasound Contrast (Microbubbles)
Devices & Specialty
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Bracco completes the four-firm club — GE HealthCare, Bayer, Guerbet and Bracco — that supplies nearly all of the world's imaging contrast, and like Guerbet it is a family-owned specialist (a Milan family company across generations) rather than a conglomerate. Its distinctive edge is a third kind of contrast most people have never heard of: ultrasound microbubbles. Bracco is a leader in gas-filled microbubble agents (SonoVue/Lumason) — tiny bubbles injected into the bloodstream that vibrate under ultrasound and light up blood flow on the screen, extending contrast imaging to ordinary, portable, radiation-free ultrasound machines. So one Italian family firm makes all three injectable-contrast chemistries — iodine for CT, gadolinium for MRI, and microbubbles for ultrasound — and pioneered the least-known of them, the only one that needs neither ionizing radiation nor a giant magnet. It's a reminder that even within the narrow world of "contrast," there are separate, concentrated supply chains for each way of seeing inside the body.
Bracco Imaging S.p.A. ↗Concentration2024
The structure of the contrast-media oligopoly is itself notable: of the four companies that supply the world's diagnostic contrast, two are sprawling conglomerates (GE HealthCare in imaging equipment, Bayer in pharma and agriculture) and two — Guerbet and Bracco — are focused, family-linked specialists for whom contrast is the whole business. Bracco, founded in Milan in 1927 and still family-controlled, built deep R&D and manufacturing in contrast chemistry and ultrasound agents, and its survival as an independent specialist alongside far larger rivals is unusual in an era of pharma consolidation. The split tells you something about the category: contrast media is too R&D- and regulation-intensive to be a casual commodity, yet too niche to dominate a conglomerate's attention — which leaves room for dedicated specialists to hold their own. But it also means the world's contrast supply rests on just four manufacturers, the same fragility seen across this radar's medical inputs, where an essential product depends on a very short list of makers.
Bracco S.p.A. ↗